SMOFLIPID 20% 6 %
MEDIUM CHAIN TRIGLYCERIDES (MCT) : 6 % OLIVE OIL : 5 % FISH OIL : 3 % SOYBEAN OIL : 6 % · DIN 02396963 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is SMOFLIPID 20%?
SMOFLIPID 20% 6 % contains MEDIUM CHAIN TRIGLYCERIDES (MCT) : 6 % OLIVE OIL : 5 % FISH OIL : 3 % SOYBEAN OIL : 6 %. It is listed in the Health Canada Drug Product Database under DIN 02396963, held by FRESENIUS KABI CANADA LTD, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Feb-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SMOFLIPID 20% used for?
Supply of energy, essential fatty acids, and omega-3 fatty acids to adults as part of parenteral nutrition when oral/enteral nutrition is impossible, insufficient, or contraindicated.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02396963 |
|---|---|
| Brand name | SMOFLIPID 20% |
| Generic / active ingredient | MEDIUM CHAIN TRIGLYCERIDES (MCT) : 6 % OLIVE OIL : 5 % FISH OIL : 3 % SOYBEAN OIL : 6 % |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 6 % |
| Dosage form | EMULSION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA02 FAT EMULSIONS |
| AHFS class | 40:20.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Feb-2016 |
| Original market date | 2013-05-08 00:00:00 |
How is it administered?
Standard dose: 1-2 g lipid/kg/day (5-10 mL/kg/day). Max infusion rate: 0.15 g lipid/kg/hour. Administer via peripheral or central vein over 12-24 hours.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-25°C. Do not freeze. (Note: General storage section 11 not fully provided in text, but standard for this product class).
How is it supplied?
100 mL (box of 10), 250 mL (box of 10), 500 mL (box of 12), 1000 mL (box of 6). Multilayered plastic bag with oxygen barrier overpouch and oxygen absorber.
Contraindications
Hypersensitivity to fish, egg, soybean, peanut; severe hyperlipidemia, liver/renal insufficiency (without dialysis), blood coagulation disorders, acute shock, unstable metabolic conditions.
Warnings and precautions
Monitor triglyceride levels; risk of fat overload syndrome. Risk of allergic reactions (soy, fish, egg). Monitor glucose, liver function, and electrolytes. Risk of metabolic acidosis.
What can be used instead?
Other Canadian products sharing ATC code B05BA02 FAT EMULSIONS. 3 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINOLEIC 20% | 16 % | EMULSION | BAXTER CORPORATION | MARKETED | DIN 02344327 |
| INTRALIPID 20% | 20 % | EMULSION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02065673 |
| 10% TRAVAMULSION LIQ IV | 1.2 G / 100 ML | LIQUID | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02016028 |
| 20% TRAVAMULSION LIQ IV | 20 G / 100 ML | LIQUID | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02016036 |
| COLIP 20% | 15 G / 100 ML | EMULSION | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02230772 |
| INTRALIPID 10% | 10 % | EMULSION | FRESENIUS KABI CANADA LTD | DORMANT | DIN 02065681 |
| INTRALIPID 30% | 30 % | EMULSION | FRESENIUS KABI CANADA LTD | DORMANT | DIN 02216175 |
| LIPOSYN II 10% | 5 % | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00720976 |
| LIPOSYN II 20% | 10 % | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00720968 |
| LIPOSYN II INJ 10% | 700 MG / 100 ML | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00818712 |
Who else supplies FAT EMULSIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FAT EMULSIONS appears in 16 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.